Figures & data
Figure 1. Selection of the study population. Abbreviations. ART, Antiretroviral therapy; BIC, Bictegravir; BMI, Body mass index; c, Cobicistat; DRV, Darunavir; EMR, Electronic medical record; FTC, Emtricitabine; HIV-1, Human immunodeficiency virus type 1; ICD-9 CM/ICD-10 CM, International Classification of Disease, 9th/10th Revision, Clinical Modification; PLWH, People living with HIV-1; TAF, Tenofovir alafenamide.
Table 1. Baseline characteristics during the 12 month period prior to the index date among weighted DRV/c/FTC/TAF and BIC/FTC/TAF cohorts.
Figure 2. Comparison of mean BMI or weight change between pre- and post-index periods. Abbreviations. BIC, Bictegravir; BMI, Body mass index; c, Cobicistat; CI, Confidence interval; DRV, Darunavir; FTC, Emtricitabine; MD, Mean difference; PLWH, People living with human immunodeficiency virus type 1; SD, Standard deviation; TAF, Tenofovir alafenamide. *p < .05. 1Doubly robust weighted MDs were obtained from weighted ordinary least squares regression adjusted for the following variables: baseline use of a protease inhibitor; use of an integrase strand transfer inhibitor; use of a non-nucleoside reverse transcriptase inhibitor; use of a beta blocker; use of insulin; and history of sleep–wake disorders, psychoses and insomnia. As the ordinary least square regression models included these variables, the doubly robust weighted MDs presented in the bar chart were not equal to the unadjusted difference in weighted means between the two cohorts that were calculated using the first two columns of results. MD >0 indicates that the BIC/FTC/TAF cohort had a larger BMI or weight gain than the DRV/c/FTC/TAF cohort. 2Nonparametric 95% CIs and p values were calculated based on 499 bootstrap resamples. At each bootstrap resample, the inverse probability of treatment weights were re-estimated.
Figure 3. Proportions of PLWH with any increase or a ≥ 5% or ≥10% increase in BMI or weight from pre- to post-index periods. Abbreviations. BIC, Bictegravir; BMI, Body mass index; c, Cobicistat; CI, Confidence interval; DRV, Darunavir; FTC, Emtricitabine; OR, Odds ratio; PLWH, People living with human immunodeficiency virus type 1; SD, Standard deviation; TAF, Tenofovir alafenamide. *p < .05. 1ORs were estimated from weighted ordinary least squares regression adjusted for the following variables: baseline use of a protease inhibitor; use of an integrase strand transfer inhibitor; use of a non-nucleoside reverse transcriptase inhibitor; use of a beta blocker; use of insulin; and history of sleep–wake disorders, psychoses and insomnia. OR >1 indicates that the BIC/FTC/TAF cohort had a higher risk of a BMI or weight gain than the DRV/c/FTC/TAF cohort. ORs for BMI and weight increases ≥10% were not assessed at 12 months because of a lack of model convergence. 2Nonparametric 95% CIs and p values were calculated based on 499 bootstrap resamples. At each bootstrap resample, the inverse probability of treatment weights were re-estimated.
Figure 4. Weighted HRs comparing weight gain or BMI increase ≥5% and ≥10% between the DRV/c/FTC/TAF and BIC/FTC/TAF cohorts. Abbreviations. BIC, Bictegravir; BMI, Body mass index; c, Cobicistat; CI, Confidence interval; DRV, Darunavir; FTC, Emtricitabine; HR, Hazard ratio; PLWH, People living with human immunodeficiency virus type 1; SD, Standard deviation; TAF, Tenofovir alafenamide. *p < .05. 1HRs were estimated from weighted Cox proportional hazards regression adjusted for the following variables: baseline use of a protease inhibitor; use of an integrase strand transfer inhibitor; use of a non-nucleoside reverse transcriptase inhibitor; use of a beta blocker; use of insulin; and history of sleep–wake disorders, psychoses and insomnia. HR >1 indicates that the BIC/FTC/TAF cohort had a higher risk of a BMI or weight gain than the DRV/c/FTC/TAF cohort. 2Nonparametric 95% CIs and p values were calculated based on 499 bootstrap resamples. At each bootstrap resample, the inverse probability of treatment weights were re-estimated.
